Sinarest wins brand of the year for marketing excellence for seventh year in succession

Sinarest recently won the prestigious brand of the year award for marketing excellence for an unprecedented seventh year in a row at the AWACS-Pharmarack Awards held in Mumbai.

Sinarest, introduced in 1983 in India, by Centaur Pharmaceuticals, is the leader in the prescription anticold market for 26 years amid intense competition from international, domestic, regional, OTC and alternate therapy brands.

Brand Sinarest registered a robust MAT growth of 57% in FY 2021-22 and holds a national market share of over 40% by value and volumes. Sinarest is the most widely prescribed anticold brand across specialities like ENT surgeons, paediatricians, consulting physicians, chest physicians and family physicians.

Two prescriptions of Sinarest are written every second by doctors in India. Sinarest is freely available in all 8 lakh pharmacies in India and is also the widely prescribed anticold brand in Uganda and Cambodia.

SD Sawant, managing director, Centaur said “Sinarest has been marketed based on evolving scientific research and rationale. Sinarest has earned the trust of doctors by consistently delivering on its promise of efficacy, safety and relief, over the past four decades.”

Centaur Pharmaceuticals also won the 1st Runner Up award for the AWACS-Pharmarack “Most Optimised Supply Chain” for their outstanding performance in distribution and logistics. Sanjay Shinde, GM- Distribution, Centaur said, “We have built efficient and effective processes and templates that deliver service excellence in the supply chain. We are delighted that our efforts have been recognized and rewarded by AWACS-Pharmarack.”

Centaur Pharmaceuticals is India’s 34th largest pharmaceutical company by prescription, with exports to 120 countries. Centaur has a presence across the pharmaceutical value chain with proficiency in API, formulations, clinical research and contract manufacturing. Centaur is India’s largest manufacturer and exporter of psychotropic API.

Centaur manufactures over 50 API, of which 28 have been launched for the first time in India. Centaur has introduced WOXHEAL for the 1st time in the world, in India for the treatment of Diabetic Foot Ulcer.

Woxheal is a new chemical entity (NCE) containing DPOCL which was co-developed with Cyto Tools Germany. Centaur successfully completed phase II/III trials in India through its CRO Lifesan, developed the API in-house, manufactured the formulation at its facilities and marketed Woxheal through their own dedicated sales team.